Japanese pharmaceutical company Takeda Pharmaceutical has partnered with Swiss drug developer AC Immune to invest up to $2.2 billion in developing a cure for Alzheimer’s disease. This collaboration aims to advance active immunotherapies targeting toxic forms of amyloid beta (Abeta) for the treatment of Alzheimer’s disease.
AC Immune will receive an upfront payment of $100 million, along with additional potential development and sales-based milestones totaling up to approximately $2.1 billion if all milestones are met. The Swiss company will also be eligible for tiered double-digit royalties on worldwide net sales.
Alzheimer’s Likelihood Linked to Genetics, Says New Study
This groundbreaking collaboration between Takeda and AC Immune represents a significant investment in the development of potential solutions for Alzheimer’s disease. Stay tuned for more updates on this promising partnership. #Takeda #Alzheimers #MedicalInnovation
\
[ad_2]
Source link
